Business
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n Sept. 6, 2023\n \n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on central nervous system (\"CNS\") and cardiovascular markets, announces that\n \n Craig Millian\n \n , Chief Executive Officer, will present at H.C. Wainwright's 25th Annual Global Investment Conference, which takes place\n \n September 11-13, 2023\n \n at the Lotte New York Palace Hotel in\n \n New York City\n \n .\n \n \n HLS will present on\n \n September 12, 2023\n \n , at\n \n 2:30 p.m. Eastern Time\n \n . The Company's presentation will be webcast at:\n \n https://journey.ct.events/view/381019f3-cd51-43fe-b0aa-b0b0699804b3\n \n . The presentation will be archived for 90 days and will also be available on the\n \n Events\n \n page in the Investor section of the Company's website.\n \n \n Mr. Millian and\n \n Tim Hendrickson\n \n , Chief Financial Officer, will also host one-on-one meetings with investors at the conference. To request a one-on-one meeting, please contact your H.C. Wainwright representative. For more information about the conference, please visit the\n \n conference website\n \n \n \n \n ABOUT HLS THERAPEUTICS INC.\n \n \n \n Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit:\n \n \n www.hlstherapeutics.com\n \n \n \n \n \n ABOUT H.C. WAINWRIGHT & CO.\n \n \n \n H.C. Wainwright is a full-service investment...